$INDV

Indivior Pharmaceuticals ended its collaboration with Addex Therapeutics on positive allosteric modulators (PAMs) ahead of its merger with Supernus. Indivior returned all PAM assets to Addex, which plans to explore strategic options for advancing its GABAB receptor portfolio. Indivior had previously discontinued another collaboration in April. The merger with Supernus is expected to create a new CNS-focused biopharma.

Indivior Pharmaceuticals (INDV) declared a $8.13 special cash dividend per share, contingent on its merger with Supernus. The dividend applies to shares and equity awards, payable on November 6, 2026, if the merger closes. INDV stock rose 0.38% to $34.35 and is up 5% in pre-market trading.

Indivior Pharmaceuticals, Inc. (INDV) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend Payment of Special Dividend Contingent upon Closing of the Pending Merger Transaction Richmond, Va., September 17, 2026 – Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) (“Indivior”) today announced that its

Indivior Pharmaceuticals, Inc. (INDV) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. Item 1.02 Termination of a Material Definitive Agreement. On September 9, 2026, Indivior UK Limited ("Indivior") and Reckitt Benckiser Healthcare (UK) Limited ("RB") entered into a Deed of Variation and Termination relating to that certain Copacker Supply Agreement dated December

Indivior Pharmaceuticals (INDV) filed an S-4 for an all-stock merger with Supernus Pharmaceuticals (SUPN). Each Supernus share will convert to 1.5401 Indivior shares. Indivior plans a $1B special dividend, contingent on merger completion, with a $650M loan to fund it. Post-merger, Indivior will rename to Supernus and trade under SUPN. The deal is expected to close in Q4 2026, subject to approvals.

Anderson Woodrow D (Chief Accounting Officer) purchased 1,500 shares of Indivior Pharmaceuticals, Inc. (INDV) at $35.69 on 2026-08-27.

Supernus Pharmaceuticals (SUPN) announced a merger with Indivior (INDV) and reported Q2 earnings. Revenue rose 32% to $219M, but net loss was $58M. The all-stock deal, pending approval, is expected to close Q4 2023. Stock closed 3% higher.

Macquarie said global biotech funding for the year through Aug. 7 rose 75% YoY, driven by IPOs up 235% and follow-ons up 138%. The XBI biotech index gained 7% in the week to Aug. 7. Braveheart Bio’s upsized IPO raised $382.5M and shares jumped 66%. Curium agreed to buy Lantheus for up to $8B, and Supernus and Indivior plan an all-stock merger.

Anderson Woodrow D (Chief Accounting Officer) purchased 1,500 shares of Indivior Pharmaceuticals, Inc. (INDV) at $36.28 on 2026-08-05.

Indivior Pharmaceuticals (NASDAQ:INDV) reported Q2 2026 adjusted EPS of $1.15 vs $0.74 expected, and revenue of $343 million vs $284.9 million expected. SUBLOCADE net revenue rose 21% to $253 million. Indivior raised FY2026 revenue guidance to $1.295B-$1.365B and SUBLOCADE guidance to $1.01B-$1.05B. Shares rose 9.22% premarket.